Minerva Neurosciences, Inc NERV
Analyst Ratings
- Consensus
- Moderate Buy — 2 Buy · 1 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $10.33 (+201.3% upside)
Key Stats
- Today's Range
- $3.28 – $3.49
- 50-Day Range
- $3.17 – $5.63
- 52-Week Range
- $1.93 – $12.46
- Volume
- 105K shs
- Average Volume
- 149K shs
- Market Cap
- $158.52 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 3.52%
- Days to Cover
- 9.18
About Minerva Neurosciences, Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Related Stocks
Compare head-to-head: NERV vs LLY·NERV vs JNJ·NERV vs ABBV·NERV vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.